M. Lebmeier

537 total citations
21 papers, 408 citations indexed

About

M. Lebmeier is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, M. Lebmeier has authored 21 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Hematology. Recurrent topics in M. Lebmeier's work include Health Systems, Economic Evaluations, Quality of Life (6 papers), Respiratory viral infections research (4 papers) and Neonatal Respiratory Health Research (4 papers). M. Lebmeier is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (6 papers), Respiratory viral infections research (4 papers) and Neonatal Respiratory Health Research (4 papers). M. Lebmeier collaborates with scholars based in United Kingdom, Germany and Netherlands. M. Lebmeier's co-authors include Mark Nuijten, Maribel Salas, Dyfrig Hughes, L. Pericleous, Dawn Lee, Anthony J. Hatswell, Robin Christensen, Roberta Ara, Peter C. Taylor and Rachid Rafia and has published in prestigious journals such as PLoS ONE, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

M. Lebmeier

19 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Lebmeier United Kingdom 10 156 121 82 80 78 21 408
Namita Tundia United States 14 65 0.4× 42 0.3× 36 0.4× 231 2.9× 34 0.4× 40 621
Marie‐Pierre Desrosiers United States 8 89 0.6× 34 0.3× 33 0.4× 35 0.4× 38 0.5× 15 491
Rajeshwari Punekar United States 10 41 0.3× 55 0.5× 110 1.3× 34 0.4× 8 0.1× 20 319
George J Joseph United States 15 51 0.3× 16 0.1× 104 1.3× 176 2.2× 39 0.5× 25 537
Saku Torvinen Finland 13 91 0.6× 334 2.8× 90 1.1× 7 0.1× 20 0.3× 43 589
Chunhuan Lao New Zealand 11 41 0.3× 83 0.7× 42 0.5× 40 0.5× 16 0.2× 57 399
James Alan Kemp United States 10 104 0.7× 262 2.2× 22 0.3× 51 0.6× 20 0.3× 12 723
Benyam Muluneh United States 12 36 0.2× 46 0.4× 106 1.3× 9 0.1× 153 2.0× 58 458
Gosia Sylwestrzak United States 9 44 0.3× 25 0.2× 159 1.9× 17 0.2× 11 0.1× 25 474
Samuel U Takvorian United States 10 31 0.2× 77 0.6× 137 1.7× 40 0.5× 4 0.1× 35 393

Countries citing papers authored by M. Lebmeier

Since Specialization
Citations

This map shows the geographic impact of M. Lebmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lebmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lebmeier more than expected).

Fields of papers citing papers by M. Lebmeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lebmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lebmeier. The network helps show where M. Lebmeier may publish in the future.

Co-authorship network of co-authors of M. Lebmeier

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lebmeier. A scholar is included among the top collaborators of M. Lebmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lebmeier. M. Lebmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muszbek, N., Carolina García‐Vidal, Keith R. Abrams, et al.. (2023). EE333 Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK. Value in Health. 26(12). S115–S115. 3 indexed citations
2.
3.
Larkin, James, Anthony J. Hatswell, Paul Nathan, M. Lebmeier, & Dawn Lee. (2015). The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLoS ONE. 10(12). e0145524–e0145524. 17 indexed citations
4.
Hatswell, Anthony J., Becky Pennington, L. Pericleous, et al.. (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes. 12(1). 140–140. 39 indexed citations
5.
McEwan, P & M. Lebmeier. (2012). PUK22 Evaluating the Minimum Renal Allograft Survival Time Required for Transplantation to Remain Cost Saving in the UK. Value in Health. 15(7). A459–A459. 1 indexed citations
6.
Winn, Bryan J., et al.. (2012). CA4 A Comparison of Patient and General-Population Utility Values for Advanced Melanoma in Health Economic Modelling. Value in Health. 15(7). A285–A285. 3 indexed citations
7.
8.
Lee, Dawn, et al.. (2012). PCN80 Modelling the Cost-Effectiveness of Ipilimumab for Previously-Treated, Metastatic Melanoma. Value in Health. 15(7). A423–A423. 3 indexed citations
9.
Guyot, Patricia, Peter C. Taylor, Robin Christensen, et al.. (2012). Indirect Treatment Comparison of Abatacept with Methotrexate Versus Other Biologic Agents for Active Rheumatoid Arthritis Despite Methotrexate Therapy in the United Kingdom. The Journal of Rheumatology. 39(6). 1198–1206. 18 indexed citations
10.
Guyot, Patricia, Peter C. Taylor, Robin Christensen, et al.. (2011). Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Research & Therapy. 13(6). R204–R204. 38 indexed citations
11.
12.
Hutchings, Andrew, et al.. (2011). PDB39 Cost-Effectiveness of Saxagliptin Compared to Sitagliptin for the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM). Value in Health. 14(7). A478–A478. 2 indexed citations
13.
Poole, C, M. Lebmeier, Roberta Ara, Rachid Rafia, & C. J. Currie. (2010). Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Lara D. Veeken. 49(10). 1949–1956. 36 indexed citations
14.
Nuijten, Mark, et al.. (2009). Cost effectiveness of palivizumab in children with congenital heart disease in Germany. Journal of Medical Economics. 12(4). 301–308. 16 indexed citations
15.
Salas, Maribel, et al.. (2009). Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature. Value in Health. 12(6). 915–922. 96 indexed citations
16.
Nuijten, Mark, et al.. (2009). Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. Journal of Medical Economics. 12(4). 291–300. 21 indexed citations
17.
Resch, Bernhard, et al.. (2008). Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clinical Therapeutics. 30(4). 749–760. 32 indexed citations
18.
Nuijten, Mark, et al.. (2007). Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children. PharmacoEconomics. 25(1). 55–71. 73 indexed citations
19.
Lebmeier, M., et al.. (2005). PIN23 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK. Value in Health. 8(6). A62–A62. 1 indexed citations
20.
Lebmeier, M., et al.. (2005). PIH1 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS. Value in Health. 8(6). A52–A52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Namita Tundia Breakdown of academic impact, for papers by Marie‐Pierre Desrosiers Breakdown of academic impact, for papers by Rajeshwari Punekar Breakdown of academic impact, for papers by George J Joseph Breakdown of academic impact, for papers by Saku Torvinen Breakdown of academic impact, for papers by Chunhuan Lao Breakdown of academic impact, for papers by James Alan Kemp Breakdown of academic impact, for papers by Benyam Muluneh Breakdown of academic impact, for papers by Gosia Sylwestrzak Breakdown of academic impact, for papers by Samuel U Takvorian
Rankless by CCL
2026